CAR Publications

Review Articles Covering CAR T Cell Therapy and Clinical Trials for B Cell Malignancies For additional information about CAR T cell therapy and the results of early clinical trials in B cell malignancies, see the following review articles.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.

Turtle CJ, Hanafi LA, Berger C, et al.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-38.

Turtle CJ, Hanafi LA, Berger C, et al.

Title: Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther. 2017. pii: S1525-0016(17)30155-7.

Rivière I, Sadelain M.

The Why, what, and How of the New FACT standards for immune effector cells. J Immunother Cancer. 2017;5:36.

Maus MV, Nikiforow S.

Showcasing Clinical Development and Production of Cellular Therapies. Mol Ther. 2017;25(4):827-828.

Levine BL, Fesnak AD, Riviere I.

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737.

Rupp LJ, Schumann K, Roybal KT, et al.

CCR7+ selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo. J Immunother Cancer. 2017;5:14.

Kueberuwa G, Gornall H, Alcantar-Orozco EM, et al.

New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21(1):89.

Kroschinsky F, Stölzel F, von Bonin S, et al; for Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group.

The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy. Mol Ther. 2017;25(2):314-320.

Bedoya F, Frigault MJ, Maus MV.

Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5:28.

Scarfò I, Maus MV.

CAR-T cells: the next era in immuno-oncology. Am J Manag Care. 2017(2 Spec No.):SP48-SP52.

Feinberg BA, Fillman J, Simoncini J, et al.

Q&A with Dr Jae Park on the promise of CAR-T cells in cancer care. Am J Manag Care. 2017(2 Spec No.):SP80-SP81.

Dangi-Garimella S.

In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One. 2016;11(12):e0166891.

Minagawa K, Jamil MO, Al-Obaidi M, et al.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262-4272.

Paszkiewicz PJ, Fräßle SP, Srivastava S, et al.

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. Comput Struct Biotechnol J. 2016;14:357-362.

Ruella M, Maus MV.

Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011.

Bonifant CL, Jackson HJ, Brentjens RJ, et al.